Indraprastha Medical Corporation Ltd

Stage 4 · Declining · week 22

As of 16 Oct 2026, Indraprastha Medical Corporation is in Stage 4 — declining, a downtrend, in week 22 (since 20 May 2026). It closed at ₹320, 48.6% below its 52-week high and below its 200-day average, which is falling. In Health Care, 40.0% of stocks are in Stage 2.

Indraprastha Medical Corporation Limited provides hospital services in India. More about the company

₹320.1
-0.44% today
₹2,934 Cr · Small cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dHospitals & Diagnostic Centres 19.4%-19.4 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is INDRAMEDCO early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-48.6%
₹319.9 lo₹622.8 hi
48.6% below 52W high — deep Stage 4 damage
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 22
1w13w26w
Week 22 — extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-17.1%
200 DMA: ₹385.9 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.22x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -4.0% vs MA50 -2.9%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-10.2%
3M
-13.7%
6M
-24.7%
YTD
-32.7%
1Y
-42.1%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 66 Stage 2 leaders. See Health Care Stage 2 →
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
19.4%
20d Δ
-19.4pp
1M return
-10.4%
3M return
-12.2%
Industry Stage-2 % · last 20 days
Industry has 5 Stage 2 leaders. See Hospitals & Diagnostic Centres Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 28w
S2 14w
S2 28w
S4 21w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 28w → S3 9w → S2 14w → S3 3w → S2 28w → S3 7w → S4 7w → S1 7w → S2 11w → S3 1w → S2 10w → S3 4w → S4 12w → S1 5w → S4 21w current
Total tracked: 168 weeks across 15 stage runs.
Scan Membership
Breakout Watch
Latest: 2025-10-13
4 appearances in last 60 days. First seen: 2024-04-08.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S4
Wk 22 · Vol 0.22x
2026-10-15S4
Wk 21 · Vol 0.27x
2026-10-14S4
Wk 21 · Vol 0.20x
2026-10-13S4
Wk 21 · Vol 1.39x
2026-10-12S4
Wk 21 · Vol 0.16x
2026-10-09S4
Wk 21 · Vol 0.38x
2026-10-08S4
Wk 20 · Vol 1.58x
2026-10-07S4
Wk 20 · Vol 0.42x
2026-10-06S4
Wk 20 · Vol 0.57x
2026-10-05S4
Wk 20 · Vol 0.32x
2026-10-01S4
Wk 20 · Vol 0.88x
2026-09-30S4
Wk 19 · Vol 1.09x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹357.3
200 DMA
₹385.9
52W High
₹622.8
52W Low
₹319.9
5D Low
₹320.1
Resistance levels (recent highs)
20d High
₹374.6
60d High
₹390.8
120d High
₹436.9
250d High
₹622.8
Next resistance
+17.0%
to 20d High
Ask the Market AI about INDRAMEDCOAsk →
P/E (TTM)
19.6
Forward 15.9
Earnings Growth (YoY)
+1.8%
Revenue +9.3%
ROE
+27.5%
Profit margin +12.4%
Dividend Yield
1.21%
P/B 5.5
About this companyHealth Care· Hospitals & Diagnostic Centres

Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive medicine, and sleep medicine. Indraprastha Medical Corporation Limited was founded in 1983 and is based in New Delhi, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.